Beyond The Pill Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Area (Diabetes, Oncology, Cardiovascular Diseases, Asthma, Others), By Offerings (Services, Monitoring, Assistance, Information, Education), By Region and Competition, 2020-2030F

November 2025 | 185 pages | ID: B32ED9D0A799EN
TechSci Research

Abstracts

The Global Beyond The Pill Market will grow from USD 282.44 Million in 2024 to USD 416.44 Million by 2030 at a 6.69% CAGR. The 'Global Beyond The Pill Market' encompasses innovative digital health solutions, services, and smart devices that extend beyond traditional pharmaceutical interventions to enhance patient engagement, treatment adherence, and overall health outcomes. Key drivers supporting this market's expansion include the increasing global prevalence of chronic diseases demanding continuous management, a growing imperative for personalized healthcare interventions, and continuous technological advancements in areas like remote monitoring and artificial intelligence.

Key Market Drivers

The increasing global burden of chronic diseases represents a primary impetus for the expansion of the 'Global Beyond The Pill Market.' As populations age and lifestyles evolve, conditions such as diabetes, cardiovascular disease, and chronic respiratory illnesses necessitate continuous management beyond traditional episodic care. These long-term conditions demand solutions that support patient adherence, facilitate remote monitoring, and enable personalized interventions, thereby moving healthcare delivery beyond solely pharmaceutical products. According to the International Diabetes Federation's (IDF) Diabetes Atlas 2025, approximately 589 million adults are living with diabetes worldwide, underscoring the immense and growing patient pool requiring innovative, integrated care models. This persistent and escalating prevalence drives the need for digital health solutions that can effectively integrate into daily life, offering sustained support and improving long-term health outcomes.

Key Market Challenges

The complex and often fragmented global regulatory landscape represents a significant impediment to the growth of the 'Global Beyond The Pill Market'. This challenge manifests as increased costs and protracted timelines for product development and market access, directly hindering the widespread adoption of innovative digital health solutions. Manufacturers must navigate disparate national and regional requirements, leading to duplicative efforts in testing, documentation, and approval processes.

The financial burden imposed by these regulatory complexities is substantial. According to a MedTech Europe 2024 Regulatory Survey, medical device manufacturers anticipate a 50% increase in maintenance and re-certification costs over a five-year cycle due to evolving regulations. This escalation in operational expenses diminishes investment capacity for research and development into new digital health technologies, effectively slowing the pace of innovation.

Key Market Trends

Strategic Expansion into Solution Provider Models is fundamentally reshaping the 'Global Beyond The Pill Market' by shifting the industry focus from standalone product sales to comprehensive, integrated digital health solutions. This trend involves medical technology companies developing ecosystems of devices, software, and supportive services to provide holistic patient management rather than episodic care. According to MedTech Europe's 'Facts & Figures 2025' published in September 2025, digital health is rapidly scaling in Europe, driven by a convergence of breakthrough technologies, patient empowerment, and systemic efficiencies within the medical technology sector. This broader strategic emphasis enhances patient engagement and offers continuous support, transforming value creation in healthcare.

Key Market Players

• F. Hoffmann-La Roche Ltd. (Flatiron Health, Inc.)
• Otsuka Pharmaceutical Co., Ltd.
• Amgen, Inc.
• AstraZeneca PLC
• Novartis AG
• Sanofi S.A.
• Novo Nordisk A/S
• Eli Lilly and Company
• Johnson & Johnson Services Inc.
• Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Beyond The Pill Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Beyond The Pill Market , By Therapeutic Area:
• Diabetes
• Oncology
• Cardiovascular Diseases
• Asthma
• Others
• Beyond The Pill Market , By Offerings:
• Services
• Monitoring
• Assistance
• Information
• Education
• Beyond The Pill Market , By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Beyond The Pill Market .

Available Customizations:

Global Beyond The Pill Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL BEYOND THE PILL MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Therapeutic Area (Diabetes, Oncology, Cardiovascular Diseases, Asthma, Others)
  5.2.2. By Offerings (Services, Monitoring, Assistance, Information, Education)
  5.2.3. By Region
  5.2.4. By Company (2024)
5.3. Market Map

6. NORTH AMERICA BEYOND THE PILL MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Therapeutic Area
  6.2.2. By Offerings
  6.2.3. By Country
6.3. North America: Country Analysis
  6.3.1. United States Beyond The Pill Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Therapeutic Area
      6.3.1.2.2. By Offerings
  6.3.2. Canada Beyond The Pill Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Therapeutic Area
      6.3.2.2.2. By Offerings
  6.3.3. Mexico Beyond The Pill Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Therapeutic Area
      6.3.3.2.2. By Offerings

7. EUROPE BEYOND THE PILL MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Therapeutic Area
  7.2.2. By Offerings
  7.2.3. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Beyond The Pill Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Therapeutic Area
      7.3.1.2.2. By Offerings
  7.3.2. France Beyond The Pill Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Therapeutic Area
      7.3.2.2.2. By Offerings
  7.3.3. United Kingdom Beyond The Pill Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Therapeutic Area
      7.3.3.2.2. By Offerings
  7.3.4. Italy Beyond The Pill Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Therapeutic Area
      7.3.4.2.2. By Offerings
  7.3.5. Spain Beyond The Pill Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Therapeutic Area
      7.3.5.2.2. By Offerings

8. ASIA PACIFIC BEYOND THE PILL MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Therapeutic Area
  8.2.2. By Offerings
  8.2.3. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Beyond The Pill Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Therapeutic Area
      8.3.1.2.2. By Offerings
  8.3.2. India Beyond The Pill Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Therapeutic Area
      8.3.2.2.2. By Offerings
  8.3.3. Japan Beyond The Pill Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Therapeutic Area
      8.3.3.2.2. By Offerings
  8.3.4. South Korea Beyond The Pill Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Therapeutic Area
      8.3.4.2.2. By Offerings
  8.3.5. Australia Beyond The Pill Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Therapeutic Area
      8.3.5.2.2. By Offerings

9. MIDDLE EAST & AFRICA BEYOND THE PILL MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Therapeutic Area
  9.2.2. By Offerings
  9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Beyond The Pill Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Therapeutic Area
      9.3.1.2.2. By Offerings
  9.3.2. UAE Beyond The Pill Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Therapeutic Area
      9.3.2.2.2. By Offerings
  9.3.3. South Africa Beyond The Pill Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Therapeutic Area
      9.3.3.2.2. By Offerings

10. SOUTH AMERICA BEYOND THE PILL MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Therapeutic Area
  10.2.2. By Offerings
  10.2.3. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Beyond The Pill Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Therapeutic Area
      10.3.1.2.2. By Offerings
  10.3.2. Colombia Beyond The Pill Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Therapeutic Area
      10.3.2.2.2. By Offerings
  10.3.3. Argentina Beyond The Pill Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Therapeutic Area
      10.3.3.2.2. By Offerings

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL BEYOND THE PILL MARKET : SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. F. Hoffmann-La Roche Ltd. (Flatiron Health, Inc.)
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Otsuka Pharmaceutical Co., Ltd.
15.3. Amgen, Inc.
15.4. AstraZeneca PLC
15.5. Novartis AG
15.6. Sanofi S.A.
15.7. Novo Nordisk A/S
15.8. Eli Lilly and Company
15.9. Johnson & Johnson Services Inc.
15.10. Teva Pharmaceutical Industries Ltd.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER